HK Stock Market Move | RIBOLIFE-B(06938) morning surged more than 3%, the company's pipeline has FIC potential, already leading into phase 2 clinical trials.

RIBOLIFE-B (06938) rose more than 3% in the morning, as of the deadline, it rose by 2.63% to 78.15 Hong Kong dollars, with a turnover of 483.137 million Hong Kong dollars. Public information shows that RiboLife is a leader in the field of small nucleic acids in China. With its independent, full-chain technology platform (especially delivery technology), rich and rapidly progressing pipeline, and huge market potential, it is considered the "Chinese version of Alnylam". Since filing for an IPO, RiboLife has attracted widespread market attention. According to the prospectus, RiboLife currently has six self-developed siRNA drugs in clinical trials, covering seven indications, with four in Phase 2 clinical trials, and more than 20 preclinical assets in continuous development. Soochow points out that by 2026, about 26.7 million people worldwide will be affected by thrombotic diseases, with the market for anticoagulant drugs estimated at around $70 billion. Targeting FXI in the current drug pipeline addresses clinical pain points, effectively avoiding bleeding risks mechanistically, and siRNA has the advantages of long duration and safety. In terms of competitive landscape, the company's pipeline has FIC potential, has already entered Phase 2 clinical trials ahead of others, and is currently in a phase 2a clinical trial for the treatment of coronary artery disease. The company expects to conduct a phase 2b clinical trial within the year. According to the Phase 1 clinical data, the company's products have shown excellent anticoagulant effects and strong safety, with no observed serious adverse events related to the drug. The bank estimates that the product has the potential to reach a peak scale of billions of dollars.